KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. PMID 39447096 · JCO Precis Oncol · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Reimagining the N-Of-1 Trial Within Pediatric Neuro-Oncology: A Shifting Paradigm. PMID 39425300 · World Neurosurg · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis. PMID 39413834 · J Natl Compr Canc Netw · 2024-Oct The record describes a retrospective exploratory biomarker analysis of the CBCSG010 Phase III trial. While the underlying trial is a randomized, Phase III drug trial with a time-to-event endpoint (DFS), this specific report is not the original primary result report. It is a secondary, post-hoc subgroup analysis focused on biomarker-defined populations ('immune-hot' vs 'immune-cold'), which is excluded per the adjudication guidelines.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of US Elastography in Thyroid Nodule Diagnosis: The ElaTION Randomized Control Trial. PMID 39404634 · Radiology · 2024-Oct The record describes a randomized trial of a diagnostic imaging technique (US elastography) for thyroid nodules. It is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention. The primary endpoint is a categorical diagnostic outcome (nondiagnostic cytologic rate), not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase I trials of single-agent new drugs in head and neck cancer: a scoping review. PMID 39390921 · Chin Clin Oncol · 2024-Oct This is a scoping review of Phase I trials in head and neck cancer. It does not report results of a single randomized Phase III/IIIb or Phase II/III trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment. PMID 39390760 · Clin Transl Med · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial. PMID 39380967 · EClinicalMedicine · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical value of modified Shenling Baizhu powder in treating targeted therapy-induced diarrhea in non-small cell lung cancer. PMID 39380231 · J Tradit Chin Med · 2024-Oct The study is a randomized controlled trial in oncology patients with a drug intervention and reports original results, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The outcomes are symptom-based (remission rate, symptom scores) and safety-focused. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided record.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Laparoscopic segmental colectomy with extensive D3 lymph node dissection for right transverse colon cancer. PMID 39370990 · J Int Med Res · 2024-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. PMID 39368878 · Clin Ther · 2024-Oct The record describes a pharmacokinetic and exposure-response analysis of venetoclax in pediatric AML patients using data from phase I studies. While it references an upcoming phase III trial (NCT05183035), it is not a report of that trial's results. It lacks the core requirement of being a report of a randomized trial with a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The efficacy endpoint discussed is complete response, which is a response rate, not a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. PMID 39315864 · NEJM Evid · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial. PMID 39304187 · J Palliat Med · 2024-Oct The study is a Phase III randomized oncology trial with a drug intervention and reports original results, but it does not evaluate a time-to-event efficacy endpoint. The primary outcome is insomnia severity (a patient-reported outcome), not overall survival, progression-free survival, or another survival/time-to-event measure.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. PMID 39303400 · Lung Cancer · 2024-Oct The record describes a phase III randomized trial of a drug intervention in oncology, but the specific analysis presented is a quality-of-life (QOL) report. It does not report on a time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR analysis, which are required for eligibility. Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. PMID 39293461 · Lancet Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. PMID 39283572 · Ann Surg Oncol · 2024-Oct Eligibility requires a randomized trial with a drug-containing intervention. This is a non-randomized trial of a device procedure (cryoablation), so it does not meet the core criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the reporting quality of pediatric neuro-oncology protocols, abstracts, and trials: Adherence to the SPIRIT and CONSORT statements. PMID 39279769 · Neurooncol Pract · 2024-Oct The record describes a methodological review assessing the reporting quality of pediatric neuro-oncology trial protocols and result articles. It is not an original formal-result report of a single randomized trial. The abstract does not present efficacy results from a specific trial with a primary/key secondary time-to-event endpoint (OS, PFS, etc.).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative stereotactic radiosurgery for patients with 1-4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694). PMID 39279766 · Neurooncol Pract · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial. PMID 39276785 · Lancet Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. PMID 39270701 · Lancet Oncol · 2024-Oct The study is a Phase 3, human, oncology trial with a drug intervention and original results. However, it is not randomized (single-arm open-label) and the primary endpoints are diagnostic sensitivity and specificity of imaging, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. Therefore, it does not meet the criteria for a therapeutic randomized trial with a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. PMID 39245060 · Lancet Oncol · 2024-Oct Study is a phase 3, randomized, oncology trial with a primary efficacy endpoint, but the intervention is radiotherapy (non-drug) and the primary endpoint is a binary pain response, not a time-to-event outcome like OS or PFS.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. PMID 39187595 · Nat Cancer · 2024-Oct Eligible for oncology, human, randomized, drug intervention, and original result criteria, but excluded due to lack of explicit Phase III/IIIb or Phase II/III designation and absence of a time-to-event primary or key secondary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. PMID 39180940 · Eur J Cancer · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003. PMID 39174706 · Esophagus · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review. PMID 39166959 · Curr Med Res Opin · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. PMID 39164407 · Leukemia · 2024-Oct The record explicitly identifies the study as a 'phase 4 BYOND trial'. The criteria require a Phase III/IIIb or Phase II/III randomized trial. Phase IV does not meet this requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. PMID 39159770 · J Clin Epidemiol · 2024-Oct The study is an observational analysis comparing methods for confounding adjustment, benchmarking a target trial emulation against a referenced RCT. It does not report results from a randomized trial itself, lacks a drug-containing intervention, and is not an original Phase III randomized trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial. PMID 39159648 · Lancet Gastroenterol Hepatol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised controlled trial. PMID 39153491 · Lancet Gastroenterol Hepatol · 2024-Oct The trial is a randomized, human, oncology-related (colorectal cancer screening) study with original results. However, it is excluded because (1) the intervention is a device/AI module (non-drug), (2) the primary and key secondary outcomes are adenoma detection rates (count/proportion), not time-to-event endpoints, and (3) the phase is not explicitly defined as Phase III/IIIb or Phase II/III in the context of a drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial. PMID 39151436 · Lancet Gastroenterol Hepatol · 2024-Oct 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of preoperative oral carbohydrate loading on postoperative insulin resistance, patient-perceived well-being, and surgical outcomes in elective colorectal surgery: a randomized controlled trial. PMID 39142436 · J Gastrointest Surg · 2024-Oct The record describes a randomized trial in an oncology setting (colorectal surgery), but it does not meet the eligibility criteria: the phase is not explicitly Phase III/IIIb or Phase II/III, the intervention is non-drug (carbohydrate loading), and the primary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS). Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Corrigendum to "Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis" [Crit. Rev. Oncol./Hematol. 201 (2024) 104416]. PMID 39127520 · Crit Rev Oncol Hematol · 2024-Oct The record is a published erratum to a systematic review and meta-analysis, not an original randomized trial report. It does not contain trial results, making it ineligible.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 39094286 · Clin Genitourin Cancer · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials. PMID 39079829 · Clin Oncol (R Coll Radiol) · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pan-cancer evaluation of tumor-infiltrating lymphocytes and programmed cell death protein ligand-1 in metastatic biopsies and matched primary tumors. PMID 39072750 · J Pathol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer. PMID 39069436 · Clin Breast Cancer · 2024-Oct The record describes a randomized Phase III trial of a pertuzumab biosimilar with a drug intervention and original primary results. However, the primary efficacy endpoint is Objective Response Rate (ORR), which is a categorical response measure, not a time-to-event outcome. There is no signal in the abstract for Kaplan-Meier analysis, time-to-event endpoints (OS, PFS, DFS, etc.), or hazard ratios, which are required for eligibility in this cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical trial of two-step photodynamic therapy for reduced pain in the treatment of precancerous squamous lesions (Actinic keratoses). PMID 39069205 · Photodiagnosis Photodyn Ther · 2024-Oct 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial. PMID 39068739 · Gynecol Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Malignant left ventricular hypertrophy and risk of cognitive impairment in SPRINT MIND trial. PMID 39067559 · Am Heart J · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Acceptability of Four Intervention Components Supporting Medication Adherence in Women with Breast Cancer: a Process Evaluation of a Fractional Factorial Pilot Optimization Trial. PMID 39060840 · Prev Sci · 2024-Oct The study is a pilot optimization trial with a process evaluation of acceptability, not a Phase III/IIIb or definitive Phase II/III trial. The primary endpoint is acceptability, not a time-to-event efficacy outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. PMID 39031276 · Rheumatol Ther · 2024-Oct The study is a randomized Phase 3 trial of a drug intervention (upadacitinib) in humans with original results, but it is not an oncology study (rheumatoid arthritis) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials. PMID 39025748 · Eur Urol · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. PMID 39014969 · BJU Int · 2024-Oct The record describes a pre-specified subgroup analysis within a randomized trial (S1500 PAPMET), focusing on outcomes by pathological subtype. While it meets criteria for oncology, human, randomized, drug intervention, and time-to-event endpoint, the report is a subgroup analysis, not the primary result of the randomized trial. Therefore, it is excluded as not being the original formal-result report for the overall drug comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501). PMID 39008208 · Ann Surg Oncol · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial. PMID 39007783 · United European Gastroenterol J · 2024-Oct The record is a subanalysis of the SORAMIC trial. While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it is excluded because it is not the primary or definitive result report of the original trial; it is a subgroup/subanalysis. Additionally, the phase of the original trial is not confirmed as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
"Mid-P strategy" versus "internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P. PMID 39004227 · Radiother Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
3D printing and intelligent technology increase convenience, reliability, and patient acceptance of ostomy nursing: a randomized controlled trial. PMID 38985377 · Updates Surg · 2024-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Long-Term Effects of Oral Nutritional Supplements After Gastrectomy for Gastric Cancer: A Survival Analysis from a Multicenter, Open-Label, Randomized Controlled Trial. PMID 38985228 · Ann Surg Oncol · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system. PMID 38979910 · Expert Rev Pharmacoecon Outcomes Res · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. PMID 38977430 · Br J Haematol · 2024-Oct The record describes a real-world, non-randomized study (CREST-UK) evaluating CPX-351 in routine practice. While it references a pivotal phase III trial and reports Kaplan-Meier OS, it does not meet the core criteria of being an original result report from a randomized Phase III or II/III drug trial. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Timing of Breast Cancer Related Lymphedema Development Over 3 Years: Observations from a Large, Prospective Randomized Screening Trial Comparing Bioimpedance Spectroscopy (BIS) Versus Tape Measure. PMID 38965099 · Ann Surg Oncol · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -